Allopeptide-pulsed dendritic cells and composite tissue allograft survival

Vu T. Nguyen, Aurele Taieb, Justin Michael Sacks, Jignesh V. Unadkat, Julio A. Clavijo, Haena Kim, Maryam Feili-Hariri, W P Andrew Lee

Research output: Contribution to journalArticle

Abstract

Composite tissue allografts (CTAs) contain their own reservoir of vascularized bone marrow, offering novel aspects for the induction of donor-specific tolerance. Additionally, the manipulation of recipient dendritic cells, pulsed with donor allopeptide, has been shown to engender solid organ allograft survival. To exploit these modalities, we have developed a protocol utilizing injection of recipient bone marrow-derived dendritic cells (BMDCs) pulsed with a donor-derived peptide for use in CTA transplantation. Six days prior to orthotopic hind-limb transplantation, Lewis rats received IV injection of donor allopeptide-pulsed, recipient BMDCs, in conjunction with a single dose of anti-lymphocyte serum. Control groups displayed signs of allograft rejection within 5 days postoperatively. Animals within the primary experimental cohort demonstrated prolongation of graft survival to an average of 8 days, and exhibited low numbers of donor T cells. The use of BMDCs in conjunction with transient immunosuppression has potential therapeutic application for induction of donor-antigen-specific tolerance to hind limb allografts.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalMicrosurgery
Volume27
Issue number2
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Composite Tissue Allografts
Tissue Survival
Dendritic Cells
Bone Marrow
Allografts
Extremities
Tissue Transplantation
Injections
Graft Survival
Immunosuppression
Transplantation
Lymphocytes
T-Lymphocytes
Antigens
Control Groups
Peptides
Serum

ASJC Scopus subject areas

  • Surgery

Cite this

Nguyen, V. T., Taieb, A., Sacks, J. M., Unadkat, J. V., Clavijo, J. A., Kim, H., ... Lee, W. P. A. (2007). Allopeptide-pulsed dendritic cells and composite tissue allograft survival. Microsurgery, 27(2), 105-111. https://doi.org/10.1002/micr.20314

Allopeptide-pulsed dendritic cells and composite tissue allograft survival. / Nguyen, Vu T.; Taieb, Aurele; Sacks, Justin Michael; Unadkat, Jignesh V.; Clavijo, Julio A.; Kim, Haena; Feili-Hariri, Maryam; Lee, W P Andrew.

In: Microsurgery, Vol. 27, No. 2, 2007, p. 105-111.

Research output: Contribution to journalArticle

Nguyen, VT, Taieb, A, Sacks, JM, Unadkat, JV, Clavijo, JA, Kim, H, Feili-Hariri, M & Lee, WPA 2007, 'Allopeptide-pulsed dendritic cells and composite tissue allograft survival', Microsurgery, vol. 27, no. 2, pp. 105-111. https://doi.org/10.1002/micr.20314
Nguyen, Vu T. ; Taieb, Aurele ; Sacks, Justin Michael ; Unadkat, Jignesh V. ; Clavijo, Julio A. ; Kim, Haena ; Feili-Hariri, Maryam ; Lee, W P Andrew. / Allopeptide-pulsed dendritic cells and composite tissue allograft survival. In: Microsurgery. 2007 ; Vol. 27, No. 2. pp. 105-111.
@article{f8d4b809330d4e3ca1e3c83dcbfc403b,
title = "Allopeptide-pulsed dendritic cells and composite tissue allograft survival",
abstract = "Composite tissue allografts (CTAs) contain their own reservoir of vascularized bone marrow, offering novel aspects for the induction of donor-specific tolerance. Additionally, the manipulation of recipient dendritic cells, pulsed with donor allopeptide, has been shown to engender solid organ allograft survival. To exploit these modalities, we have developed a protocol utilizing injection of recipient bone marrow-derived dendritic cells (BMDCs) pulsed with a donor-derived peptide for use in CTA transplantation. Six days prior to orthotopic hind-limb transplantation, Lewis rats received IV injection of donor allopeptide-pulsed, recipient BMDCs, in conjunction with a single dose of anti-lymphocyte serum. Control groups displayed signs of allograft rejection within 5 days postoperatively. Animals within the primary experimental cohort demonstrated prolongation of graft survival to an average of 8 days, and exhibited low numbers of donor T cells. The use of BMDCs in conjunction with transient immunosuppression has potential therapeutic application for induction of donor-antigen-specific tolerance to hind limb allografts.",
author = "Nguyen, {Vu T.} and Aurele Taieb and Sacks, {Justin Michael} and Unadkat, {Jignesh V.} and Clavijo, {Julio A.} and Haena Kim and Maryam Feili-Hariri and Lee, {W P Andrew}",
year = "2007",
doi = "10.1002/micr.20314",
language = "English (US)",
volume = "27",
pages = "105--111",
journal = "Microsurgery",
issn = "0738-1085",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Allopeptide-pulsed dendritic cells and composite tissue allograft survival

AU - Nguyen, Vu T.

AU - Taieb, Aurele

AU - Sacks, Justin Michael

AU - Unadkat, Jignesh V.

AU - Clavijo, Julio A.

AU - Kim, Haena

AU - Feili-Hariri, Maryam

AU - Lee, W P Andrew

PY - 2007

Y1 - 2007

N2 - Composite tissue allografts (CTAs) contain their own reservoir of vascularized bone marrow, offering novel aspects for the induction of donor-specific tolerance. Additionally, the manipulation of recipient dendritic cells, pulsed with donor allopeptide, has been shown to engender solid organ allograft survival. To exploit these modalities, we have developed a protocol utilizing injection of recipient bone marrow-derived dendritic cells (BMDCs) pulsed with a donor-derived peptide for use in CTA transplantation. Six days prior to orthotopic hind-limb transplantation, Lewis rats received IV injection of donor allopeptide-pulsed, recipient BMDCs, in conjunction with a single dose of anti-lymphocyte serum. Control groups displayed signs of allograft rejection within 5 days postoperatively. Animals within the primary experimental cohort demonstrated prolongation of graft survival to an average of 8 days, and exhibited low numbers of donor T cells. The use of BMDCs in conjunction with transient immunosuppression has potential therapeutic application for induction of donor-antigen-specific tolerance to hind limb allografts.

AB - Composite tissue allografts (CTAs) contain their own reservoir of vascularized bone marrow, offering novel aspects for the induction of donor-specific tolerance. Additionally, the manipulation of recipient dendritic cells, pulsed with donor allopeptide, has been shown to engender solid organ allograft survival. To exploit these modalities, we have developed a protocol utilizing injection of recipient bone marrow-derived dendritic cells (BMDCs) pulsed with a donor-derived peptide for use in CTA transplantation. Six days prior to orthotopic hind-limb transplantation, Lewis rats received IV injection of donor allopeptide-pulsed, recipient BMDCs, in conjunction with a single dose of anti-lymphocyte serum. Control groups displayed signs of allograft rejection within 5 days postoperatively. Animals within the primary experimental cohort demonstrated prolongation of graft survival to an average of 8 days, and exhibited low numbers of donor T cells. The use of BMDCs in conjunction with transient immunosuppression has potential therapeutic application for induction of donor-antigen-specific tolerance to hind limb allografts.

UR - http://www.scopus.com/inward/record.url?scp=33947170905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947170905&partnerID=8YFLogxK

U2 - 10.1002/micr.20314

DO - 10.1002/micr.20314

M3 - Article

C2 - 17290380

AN - SCOPUS:33947170905

VL - 27

SP - 105

EP - 111

JO - Microsurgery

JF - Microsurgery

SN - 0738-1085

IS - 2

ER -